tbuckley/cabot-search huggingface dataset:
HYSTERICAL PYREXIA.
Journal: JAMA (1900)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
BCG Vaccination
Authors: ROB ROY MACGREGOR
Journal: Annals of Internal Medicine (1970)

Letters and Comments1 August 1970BCG VaccinationROB ROY MACGREGOR, M.D., C. KIRT AVENT, M.D., GEORGE W. COUNTS, M.D., JAMES B. DEMAINE, M.D., M. COLIN JORDAN, M.D., JON E. ROSENBLATT, M.D.ROB ROY MACGREGOR, M.D.Search for more papers by this author, C. KIRT AVENT, M.D.Search for more papers by this author, GEORGE W. COUNTS, M.D.Search for more papers by this author, JAMES B. DEMAINE, M.D.Search for more papers by this author, M. COLIN JORDAN, M.D.Search for more papers by this author, JON E. ROSENBLATT, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-73-2-339 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the Editor: We were pleased to see Dr. Smith's article on Bacillus-Calmette-Guérin (BCG) vaccination in the March ANNALS(Ann Intern Med72:419-422, 1970). His rebuttal by documented studies of the common arguments against its use seemed fair and convincing. We only wish that he had included American Indians and Eskimos in his list of high-risk groups. U. S. Public Health Service data (1) show that Indians have 10 times the incidence of active tuberculosis than white Americans. This point has been made graphically for us by the large number of active cases we have seen among Indians, many in...References1. Reported Tuberculosis Data—1968. U. S. Public Health Service Publication No. 638:5, 17, 1970 Google Scholar2. Public Health Service recommendations on the use of BCG vaccination in the United States. Amer Rev Resp Dis 95:524, 1967 Google Scholar3. ARONSONARONSONTAYLOR JCH: A twenty-year appraisal of BCG vaccination in the control of tuberculosis. Arch Intern Med (Chicago) 101:881, 1958 CrossrefGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: University of Washington Seattle, Wash. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 August 1970Volume 73, Issue 2Page: 339-340KeywordsBacille calmette guerinMedical servicesNative American people ePublished: 1 December 2008 Issue Published: 1 August 1970 PDF downloadLoading ...
Role of nitric oxide in the synthesis of guanidinosuccinic acid, an activator of the N-methyl-d-aspartate receptor
Authors: Kazumasa Aoyagi, Siranoush Shahrzad, Satomi Iida, Chie Tomida, Aki Hirayama, Sohji Nagase, Katsumi Takemura, Akio Koyama, Shoji Ohba, Mitsuharu Narita, Burton D. Cohen
Journal: Kidney International (2001)
Small Pox.
Journal: JAMA (1883)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract P300: A Novel Highly Selective Adenosine A <sub>1</sub> Receptor Agonist (VCP28) Reduces Ischemia/Reperfusion Injury at Concentrations that Do Not Affect Heart Rate
Authors: Paul J White, Vijay Urmaliya, Colin W Pouton, Shane Devine, Peter Scammells
Journal: Circulation Research (2011)

Whilst adenosine A1 receptor agonists have repeatedly been shown to protect the ischaemic myocardium, the clinical use of these agents is limited by strong cardiodepressant effects. The cardioprotective effects of a novel adenosine A1 receptor agonist N6-(2,2,5,5-tetramethylpyrrolidin-1-yloxyl-3-ylmethyl) adenosine (VCP28) were compared with the selective adenosine A1receptor agonist N6-cyclopentyladenosine (CPA) in a H9c2(2–1) cardiac cell line-simulated ischemia (SI) model (12 hours) and a global ischemia (30 minutes) and reperfusion (60 minutes) model in isolated rat heart model. H9c2(2–1) cells were treated with CPA and VCP28 at the start of ischemia for entire ischemic duration, whereas isolated rat hearts were treated at the onset of reperfusion for 15 minutes. In a H9c2(2–1) cell SI model, CPA and VCP28 (100 nM) significantly (P , 0.05, n = 5–6) reduced the proportion of nonviable cells (30.88% 6 2.49% and 16.17% 6 3.77% of SI group, respectively) and lactate dehydrogenase efflux. In isolated rat hearts, CPA and VCP28 significantly (n = 6–8, P , 0.05) improved postischemic contractility (dP/dtmax, 81.69% 6 10.96%, 91.07% 6 19.87% of baseline, respectively), left ventricular developed pressure, and end diastolic pressure and reduced infarct size. The adenosine A1 receptor antagonist DPCPX abolished the cardioprotective effects of CPA and VCP28 in both models. At the concentrations used in the ischaemia models, VCP28 had no effect on heart rate, unlike CPA. In conclusion, the adenosine A1 receptor agonist VCP28 has cardioprotective equal effects to the prototype A1 agonist CPA at concentrations that have no effect on heart rate.
Tests of blood coagulation and hemostasis. I. The prothrombin time
Authors: P. Didisheim
Journal: JAMA (1966)

Probably the most widely used of all clotting tests, Quick's prothrombin time (PT)<sup>1</sup>is perhaps the least well understood. Despite its name, we now know that the PT is relatively insensitive to prothrombin (factor II). The test measures the rate of conversion of prothrombin to thrombin in the presence of a tissue extract (thromboplastin) and calcium ions, followed by the polymerization of fibrinogen by thrombin to fibrin. The PT is influenced by the concentrations of four clotting factors besides prothrombin: I (fibrinogen), V (labile factor), VII (stable factor), and X (Stuart-Prower factor). In addition, heparin prolongs the PT, a point frequently overlooked in managing patients treated with anticoagulants. However, the sensitivity of the PT to many factors is the very reason that it is so useful clinically. In patients receiving anticoagulants orally, deficiencies develop in four clotting factors: prothrombin, VII, IX (plasma thromboplastin component), and X. Factor VII decreases
Tricyclic plasma levels. Effect of age, race, sex, and smoking
Authors: V. E. Ziegler
Journal: JAMA (1977)

Steady-state plasma tricyclic antidepressant levels were determined in 65 patients undergoing treatment for depression with either amitriptyline hydrochloride or nortriptyline hydrochloride to determine if common factors such as age, race, sex, or smoking status were predictors of steady-state drug levels that have been shown to vary up to 36-fold. Evaluation of these factors did not disclose differences in the rate of demethylation of amitriptyline to nortriptyline, or steady-state tricyclic levels in the amitriptyline-treated patients. No differences were found in the nortriptyline-treated patients except regarding race. Black patients had significantly higher (50%) nortriptyline plasma levels than did white patients, which may explain the more rapid response to tricyclic treatment demonstrated in blacks. Decreased rates of nortriptyline metabolism in blacks can result in Increased side effects and treatment failure if the therapeutic plasma range is exceeded. (<i>JAMA</i>238:2167-2169, 1977)
Association between income distribution and health changes with level of economic development
Journal: BMJ (1999)

H pylori is weakly associated with heart diseaseChronic infection with Helicobacter pylori may be an avoidable cause of coronary heart disease, but most studies have been too small and prone to bias to assess this reliably.Danesh et al (p 1157) report two of the largest case-control studies so far.A study of 1122 cases of early onset myocardial infarction (average age 44 years) and 1122 age and sex matched controls found that myocardial infarction is about twice as common in people with serological evidence of persistent H pylori infection than in others.A weaker trend was found in a separate study of 510 sibling pairs.The authors conclude that in the context of previously published studies, their results show a weak association between H pylori and early onset heart disease.
Incorrect Dosage in: A 70-Year-Old Man With a Transient Ischemic Attack
Authors: Philip Smith, Michael Kaufmann, Lona Mody, A Smith, Mody Kaufmann, Mody Kaufmann, Connie Wagner
Journal: JAMA (2008)

Regarding surge capacity, 168 (37%) of the respondents reported they would have beds available to take hospital overflow, and few (32, 7%) would consider discharging residents to make room for patients (Table 2).Facilities were more likely to accept noninfluenza patients than influenza patients requiring low levels of care (263 [58%] vs 170 [38%]).In general, Michigan and Nebraska nursing home respondents did not differ greatly in their reported levels of pandemic planning; however, Nebraska nursing homes were more likely to have given staff introductory pandemic education while Michigan nursing homes were more likely to have stockpiled supplies, have mental health services available, and have undertaken other planning activities (Table 2).Comment.In these 2 states, we found that although many nursing homes have undertaken some pandemic influenza preparedness planning, only 23% have a specific pandemic response plan.Many nursing homes have staff training plans, adequate laboratory access, available mental health services, and procedures for handling family and visitors during a pandemic.However, about half had not established lines of communication with state and local public health officials or with nearby hospitals, suggesting the potential for improved community-wide coordination.Study limitations included that the survey was from only 2 states and we did not perform any qualitative assessments.In addition, this was a self-administered questionnaire with a potential for reporter bias.There were no data to compare rural vs urban nursing homes.Nevertheless, these results may be useful to national public health planners to better define the role of nursing homes in an influenza pandemic.
Abstract 3509: Knockdown of RNF2 induces apoptosis by regulating MDM2 and p53 stability
Authors: Weihong Wen, Cong Peng, Myoung Ok Kim, Chul Ho Jeong, Feng Zhu, Ke Yao, Tatyana Zykova, Wei-Ya Ma, Andria Carper, Alyssa Langfald, Ann M. Bode, Zigang Dong
Journal: Cancer Research (2016)

Abstract RNF2, also known as Ring1B/Ring2, is a component of the polycomb repression complex 1 (PRC1). RNF2 is highly expressed in many tumors, suggesting that it might have an oncogenic function, but the mechanism is unknown. Here we show that knockdown of RNF2 significantly inhibits both cell proliferation and colony formation in soft agar, and induces apoptosis of cancer cells. Knockdown of RNF2 in HCT116 p53+/+ cells resulted in significantly more apoptosis than was observed in RNF2 knockdown HCT116 p53−/− cells, indicating that RNF2 knockdown-induced apoptosis is partially dependent on p53. Various p53-targeted genes were increased in RNF2 knockdown cells. Further studies revealed that in RNF2 knockdown cells, the p53 protein level was increased, the half-life of p53 was prolonged and p53 ubiquitination was decreased. In contrast, cells overexpressing RNF2 showed a decreased p53 protein level, a shorter p53 half-life and increased p53 ubiquitination. Importantly, we found that RNF2 directly binds with both p53 and MDM2 and promotes MDM2-mediated p53 ubiquitination. RNF2 over-expression could also increase the half-life of MDM2 and inhibit its ubiquitination. The regulation on p53 and MDM2 stability by RNF2 was observed during the etoposide-induced DNA damage response. These results provide a possible mechanism explaining the oncogenic function of RNF2, and because RNF2 is important for cancer cell survival and proliferation, it might be an ideal target for cancer therapy or prevention. Keywords: RNF2, p53, apoptosis Citation Format: Weihong Wen, Cong Peng, Myoung Ok Kim, Chul Ho Jeong, Feng Zhu, Ke Yao, Tatyana Zykova, Wei-Ya Ma, Andria Carper, Alyssa Langfald, Ann M. Bode, Zigang Dong. Knockdown of RNF2 induces apoptosis by regulating MDM2 and p53 stability. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 3509.
Intestinal Antibodies
Authors: W. Allan Walker, Kurt J. Isselbacher
Journal: New England Journal of Medicine (1977)

The mucosal surface of the gastrointestinal tract represents an extensive area that must be protected from penetration by pathologic organisms and toxic agents in the environment. An important, if not the most important, component of host defense at the epithelial surface is the presence of intestinal antibodies. These antibodies control bacterial proliferation, neutralize viruses and prevent penetration of enterotoxins and intestinal antigens. A deficiency in local intestinal antibodies can severely impair mucosalbarrier function, resulting in uptake of noxious substances that could contribute to the pathogenesis of intestinal or systemic disease.During the last decade, several important observations have contributed to . . .
Life-threatening Mycoplasma pneumoniae pneumonia
Authors: E. R. Noriega
Journal: JAMA (1974)

PNEUMONIA caused by<i>Mycoplasma pneumoniae</i>is usually a mild and self-limited infection. However, several overwhelming or fatal instances have been reported, usually in individuals with underlying systemic disease.<sup>1</sup>We shall describe a previously healthy young man who became critically ill with pneumonitis caused by this organism. His clinical course and response to therapy are presented to further characterize the nature of severe pneumonitis due to<i>M pneumoniae</i>. <h3>Report of a Case</h3> A 25-year-old man was hospitalized after two days of fever, chest pain, and cough productive of scant, yellow sputum. His temperature was 38.8 C (102 F); blood pressure, 120/90 mm Hg; pulse, 100 beats per minute, and respirations, 20/min. Dullness and bronchial breath sounds were noted at the lung bases. The remainder of the physical examination showed no abnormalities. The peripheral white blood cell count was 8,600/cu mm, with a normal differential. Serum cold agglutinins were absent. A
The Croonian Lectures ON MUSCULAR MOVEMENTS AND THEIR REPRESENTATION IN THE CENTRAL NERVOUS SYSTEM: Delivered before the Royal College of Physicians of London
Authors: C. E. Beevor
Journal: BMJ (1903)

I 2 MTxICLOiaL] CROONIAN LECTURES.[Jn 4, I93.chapter of the work.The rest consists of a collection of medical receipts, differing from those in the other books of the Anglo-Saxon library.It is entirely free from charms and superstitions, and the prescriptions are for the most part simpler than those of the Anglo-Saxon leeches.This treatise has been shown by a German philologist, Dr. Max Loweneck, to be based upon a Latin work belonging to the first period of the school of Salerno-namely the Practica of Petroncellus or Petronius, a work written probably about A.D. 1035, and printed in the Collectio Salernitana.One frag- ment has been traced to the writings of another SaJernitan teacher, Gariopontus, of the same period.But these identi- fications do not account for the whole of the Anglo-Saxon text, and it does not seeaii that this was translated directly from the Latin.The actual origin of the work is therefore still somewhlat obscure.The date of this man-uscript is the first half of the twelfth century, probably before I150.It shows that the Anglo-Saxons were beginniing to profit by the teaching of the school of Salerno before that school was influenced by thle Arabian medicine.It also sh1ows that the Anglo-Saxon medicine, like the other early English written literature went on for some time after the Norman Conquest.To this same period belongs another MS., which contains a version of the Herbarium of Apuleius later than that pre- viously spoken of.This is not included in Mr. Cockaynie's Leechdoms, but has been published in Germany, as edited by Herr Berbericli.This MS. is referred to the middle of the twelfth century, about 1150.It therefore touches on the extreme limit of Anglo-Saxon written litera- ture-and, indeed, is described by Herr Berberich as " early middle English "-but, like the last-mentioned work, slhows the long continuance of Anglo-Saxon medicine after the Conquest.This work closes the early English medical library, and, as the celebrated Anglo-Saxon Chronicle came to an end in I 155, the general literature and medical literature of our early ancestors reached their limit about the same time.
STATE EXAMINATIONS AND SCHOOLS OF MEDICINE.
Journal: JAMA (1889)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
MORE SANITARY SLEEPING-CAR ACCOMMODATIONS NEEDED.
Journal: JAMA (1901)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
New Drugs and Developments in Therapeutics
Authors: Drugs for Mental Illness
Journal: JAMA (1961)

In 1954, there was introduced into American medicine, against a background of extensive European investigation, a drug with a remarkable diversity of effects: antihistaminic, antiemetic, sedative, as well as less prominent local anesthetic, hypothermic, adrenolytic, anticholinergic, and curare-like actions. The drug was, of course, chlorpromazine (Thorazine), a derivative of phenothiazine. Although it was by no means the first phenothiazine compound introduced, none of the earlier compounds met with the commercial success of chlorpromazine, which, in addition to its other uses, rapidly gained acceptance as a valuable agent for the alleviation of anxiety associated with mental illness. Doubtlessly prompted by this success, American pharmaceutical manufacturers subsequently introduced, and continue to introduce, a procession of other phenothiazine derivatives; more than a dozen are now available. Some are promoted primarily as "tranquilizers," others as antiemetic or antihistaminic agents. Many offer only questionable advantages over chlorpromazine, and some authorities doubt that any of these
REPORT OF THE SURGICAL CLINICS,Held at the Western Pennsylvania Hospital, before the Students of the Western Pennsylvania Medical College,
Authors: J. B. MURDOCH
Journal: JAMA (1892)

[Reported by E. E. Wible, M.D., a member of the Graduating Class.] (Continuedfrom page 389.) There is lengthening of the arm in all the forms except the subclavicular; in the subglenoid there is the most lengthening, which is about an inch. In a fracture of the humérus, the depression below the acromion is not so marked as in luxation. Calloway's test is to measure with a tape-line the circumference of the shoulder, passing the tape through the axilla and over the acromion process of each scapulae, when it would be found that the injured shoulder would measure about an inch more than the sound one. This was said by Mr. Calloway to be an infallible test. There is one exception to this test, that is in a fracture of the neck of the scapula; but it is a very rare form of fracture. Dugas' test is to put the hand